publication . Article . Other literature type . 2019

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer

Ricardo Leão; Donghyun Lee; Arnaldo Figueiredo; Thomas Hermanns; Peter Wild; Martin Komosa; Irene Lau; Mathew Mistry; Nuno Miguel Nunes; Aryeh J. Price; ...
Open Access English
  • Published: 01 Apr 2019
  • Publisher: Wiley
Abstract
What's new? Telomerase reverse transcriptase (TERT) activation is central to cancer cell immortalization. It acts, however, through relatively unknown mechanisms. In urothelial bladder cancer (UBC) in particular, TERT activation can occur in the presence or absence of mutation, raising questions about alternative activation mechanisms. Our study shows that hypermethylation of the TERT promoter (THOR) plays a key part in UBC, being a dynamic and progressive process, with hypermethylation levels increasing with bladder cancer severity. Moreover, both hypermethylation and TERT promoter mutation contributed to increased telomerase expression. The findings provide in...
Subjects
free text keywords: Urothelial bladder cancer, Telomerase, TERT promoter methylation, TERT promoter mutations, Recurrence, Progression, Institute of Pathology and Molecular Pathology, Urological Clinic, 610 Medicine & health, Tumor Markers and Signatures, Cancer Research, Oncology, Medicine, business.industry, business, Disease, DNA methylation, Bladder cancer, medicine.disease, Telomere, Cancer, Carcinogenesis, medicine.disease_cause, Epigenetics
Funded by
FCT| UID/BIM/04773/2013
Project
UID/BIM/04773/2013
Centre for Biomedical Research
  • Funder: Fundação para a Ciência e a Tecnologia, I.P. (FCT)
  • Project Code: 147344
  • Funding stream: 5876
37 references, page 1 of 3

1 Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.25220842 [PubMed]

2 SEER Cancer Stat Facts: Bladder Cancer [Internet]. 2014. Available from: http://seer.cancer.gov/statfacts/html/urinb.html.

3 Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015;15:25–41.25533674 [PubMed]

4 Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5. discussion 75–7.16442208 [PubMed]

5 Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol 1998;22:1435–48.9850170 [PubMed]

6 Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of Tumours of the urinary system and male genital organs‐part B: prostate and bladder Tumours. Eur Urol 2016;70:106–19.26996659 [PubMed]

7 Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet 2016;388:2796–810.27345655 [PubMed]

8 Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43(2 Pt 1):405–13.3907856 [PubMed]

9 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.21376230 [OpenAIRE] [PubMed]

10 Greider CW. Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 1998;95:90–2.9419332 [OpenAIRE] [PubMed]

11 Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5.7605428 [PubMed]

12 Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787–91.9282118 [OpenAIRE] [PubMed]

13 Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997;33:761–6.9282114 [OpenAIRE] [PubMed]

14 Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 2017;49:349–57.28135248 [OpenAIRE] [PubMed]

15 Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4:2185.23887589 [OpenAIRE] [PubMed]

37 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2019

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer

Ricardo Leão; Donghyun Lee; Arnaldo Figueiredo; Thomas Hermanns; Peter Wild; Martin Komosa; Irene Lau; Mathew Mistry; Nuno Miguel Nunes; Aryeh J. Price; ...